Literature DB >> 6694976

Bromocriptine inhibits growth hormone release from rat pituitary cells in primary culture.

M J Cronin, M O Thorner, P Hellmann, A D Rogol.   

Abstract

The action of the potent dopamine receptor agonist bromocriptine was studied in primary cultures of rat anterior pituitary cells. Bromocriptine inhibited both prolactin and growth hormone release in a concentration-dependent manner. This effect was blocked by the dopamine receptor antagonist spiperone when the agonist and antagonist were added coincidently. In contrast, spiperone was unable to affect the actions of bromocriptine if added 1 min after bromocriptine application or later. These results suggest that dopamine receptors exist not only on mammotrophs, but also on somatotrophs in vitro.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6694976     DOI： 10.3181/00379727-175-41787

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


  9 in total

1.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

2.  Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland.

Authors:  Rosario Pivonello; Marlijn Waaijers; Johan M Kros; Claudia Pivonello; Cristina de Angelis; Alessia Cozzolino; Annamaria Colao; Steven W J Lamberts; Leo J Hofland
Journal:  Endocrine       Date:  2016-10-13       Impact factor: 3.633

3.  The effects of bromocriptine and prolactin on porphyrin biosynthesis and morphology in the female hamster harderian gland.

Authors:  S W Shah; J McGadey; M R Moore; T Houston; A P Payne
Journal:  J Comp Physiol B       Date:  1996       Impact factor: 2.200

4.  Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome.

Authors:  A Heinz; B Lichtenberg-Kraag; S S Baum; K Graf; F Kruger; M Dettling; H Rommelspacher
Journal:  J Neural Transm Gen Sect       Date:  1995

5.  Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.

Authors:  Leonardo Vieira Neto; Evelyn de O Machado; Raul M Luque; Giselle F Taboada; Jorge B Marcondes; Leila M C Chimelli; Leonardo Pereira Quintella; Paulo Niemeyer; Denise P de Carvalho; Rhonda D Kineman; Mônica R Gadelha
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

Review 6.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

7.  The effects of bromocriptine and prolactin on porphyrin biosynthesis in the harderian gland of the male hamster, Mesocritecus auratus.

Authors:  F A Marr; S W Shah; J McGadey; M R Moore; T Houston; A P Payne
Journal:  J Comp Physiol B       Date:  1995       Impact factor: 2.200

Review 8.  Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Authors:  Claudia Pivonello; Roberta Patalano; Mariarosaria Negri; Rosa Pirchio; Annamaria Colao; Rosario Pivonello; Renata Simona Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

Review 9.  The dopaminergic control of Cushing's syndrome.

Authors:  R Pivonello; C Pivonello; C Simeoli; M C De Martino; A Colao
Journal:  J Endocrinol Invest       Date:  2022-04-23       Impact factor: 5.467
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.